Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Year: 2020
Type: article
Abstract: In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.
Source: Leukemia
Authors: A. Kuendgen, M. Nomdedeu, H. Tuechler, G. Garcia-Manero, R. S. Komrokji, M. A. Sekeres, M. G. Della Porta, M. Cazzola, A. E. DeZern, G. J. Roboz, D. P. Steensma, A. A. Van de Loosdrecht, R. F. Schlenk, J. Grau, X. Calvo, S. Blum, A. Pereira, P. Valent, D. Costa, A. Giagounidis, B. Xicoy, H. Döhner, U. Platzbecker, C. Pedro, M. Lübbert, I. Oiartzabal, M. Díez-Campelo, M. T. Cedena, S. Machherndl-Spandl, M. López-Pavía, C. D. Baldus, M. Martinez-de-Sola, R. Stauder, B. Merchan, A. List, C. Ganster, T. Schroeder, M. T. Voso, M. Pfeilstöcker, H. Sill, B. Hildebrandt, J. Esteve, B. Nomdedeu, F. Cobo, R. Haas, F. Sole, U. Germing, P. L. Greenberg, D. Haase, G. Sanz
Institutions: Düsseldorf University Hospital, Institut Català d'Oncologia, Hanusch Hospital, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Cleveland Clinic, Humanitas University, IRCCS Humanitas Research Hospital, Policlinico San Matteo Fondazione, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Dana-Farber Cancer Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, German Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, University Hospital Ulm, Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Centre Hospitalier Universitaire Vaudois, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Universitat Autònoma de Barcelona, Josep Carreras Leukaemia Research Institute, University Hospital Leipzig, University of Freiburg, University Medical Center Freiburg, Hospital Universitario Araba, Complejo Hospitalario de Salamanca, Hospital Universitario 12 De Octubre, Krankenhaus der Elisabethinen, Hospital General Universitario De Valencia, University Hospital Schleswig-Holstein, Corporació Sanitària Parc Taulí, Innsbruck Medical University, Universität Innsbruck, Vall d'Hebron Hospital Universitari, Universitätsmedizin Göttingen, University of Rome Tor Vergata, Medical University of Graz, Heinrich Heine University Düsseldorf, Hospital Quirón Teknon, Stanford University, Hospital Universitari i Politècnic La Fe
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: therapy-related myelodysplastic syndrome, WHO classification, risk stratification, prognostic scoring, IPSS-R, chromosomal abnormalities, time to transformation, survival, primary myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, therapy-related acute myeloid leukemia, FAB classification
Open Access status: hybrid
Estimated APC paid: $4,480
OpenAlex ID: W3037094020
